Cancer Anorexia-Cachexia Syndrome (CACS) Market Forecast: How Big Will It Be by 2030?
Uncover key drivers, emerging technologies, and competitive movements shaping the cancer anorexia-cachexia syndrome (cacs) market from 2026–2035 with trusted insights from The Business Research Company
Across 2026–2030, what is the expected market valuation path of the Cancer Anorexia-Cachexia Syndrome (CACS) Market?
The cancer anorexia-cachexia syndrome (cacs) market has experienced rapid growth over recent years. Its valuation is expected to increase from $3.88 billion in 2025 to $4.29 billion in 2026, achieving a compound annual growth rate (CAGR) of 10.7%. This historic growth can be attributed to several factors including the rising prevalence of advanced cancer cases, an increased understanding of cachexia’s influence on treatment outcomes, the early adoption of appetite stimulants in clinical settings, the proliferation of hospital-based supportive care programs, and the expansion of research in oncology nutrition.
The market for cancer anorexia-cachexia syndrome (CACS) is projected to experience swift expansion in the coming years. This market is anticipated to reach a valuation of $6.37 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 10.4%. Factors contributing to this growth during the projected timeframe include greater financial commitments to developing cachexia drugs, an increasing emphasis on personalized supportive care in oncology, intensified clinical trial efforts for new therapeutic agents, the broadening availability of cancer care delivered at home, and the enhanced incorporation of cachexia management strategies into standard oncology protocols. Key trends anticipated during this period encompass the escalating creation of targeted treatments for cachexia, a heightened interest in anti-inflammatory therapeutic routes, the increasing embrace of combined treatment methodologies, the widening scope of nutritional and metabolic support options, and a stronger focus on intervening in cachexia at an earlier stage.
Access Your Free Sample Report for In-Depth Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21125&type=smp
Which Drivers Are Supporting The Rise Of The Cancer Anorexia-Cachexia Syndrome (CACS) Market?
The increasing incidence of cancer is anticipated to fuel the expansion of the cancer anorexia-cachexia syndrome market in the future. Cancer encompasses a range of illnesses characterized by the unchecked proliferation and dissemination of abnormal cells within the body. The global rise in cancer rates can be attributed to various factors, including an aging demographic, shifts in lifestyle, exposure to environmental hazards, enhanced diagnostic techniques, increased public awareness, alongside genetic predispositions and specific infection-related cancers. Cancer anorexia-cachexia syndrome (CACS) plays a crucial role in addressing this increasing cancer burden by focusing on the management of severe weight loss and malnutrition frequently observed in cancer patients, thereby enhancing their overall quality of life and improving treatment outcomes. For instance, a report from Macmillan Cancer Support, a UK-based charitable organization, released in August 2024, indicated that more than 3 million individuals in the UK are currently living with cancer, a figure projected to rise to 3.5 million by 2025, 4 million by 2030, and 5.3 million by 2040. Consequently, the escalating prevalence of cancer acts as a key driver for the growth of the cancer anorexia-cachexia syndrome market.
What Leading Segments Are Studied In The Cancer Anorexia-Cachexia Syndrome (CACS) Market?
The cancer anorexia-cachexia syndrome (cacs) market covered in this report is segmented –
1) By Indication: Weight Loss Prevention, Appetite Loss, Muscle Wasting, Inflammation, Other Indications
2) By Therapeutics: Progestogen, Corticosteroid, Combination Therapy, Other Therapeutics
3) By Mechanism Of Action: Appetite Stimulants, Anti-inflammatory Agents, Hormone Therapies, Cannabinoids, Other Mechanism Of Actions
4) By Route of Administration: Oral, Intravenous, Subcutaneous, Other Routes of Administration
5) By Application: Hospitals, Clinics, Home Care
Subsegments:
1) By Weight Loss Prevention: Nutritional Supplements, Metabolic Modulators
2) By Appetite Loss: Appetite Stimulants, Ghrelin Receptor Agonists
3) By Muscle Wasting: Anabolic Agents, Selective Androgen Receptor Modulators (SARMs)
4) By Inflammation: Anti-Inflammatory Drugs, Cytokine Inhibitors
5) By Other Indications: Combination Therapies, Supportive Care Interventions
How Are New Market Trends Shaping The Landscape Of The Cancer Anorexia-Cachexia Syndrome (CACS) Market?
Major companies operating within the cancer anorexia-cachexia syndrome market are prioritizing the creation of innovative solutions, including monoclonal antibody therapies, to elevate treatment efficacy, enhance patient outcomes, and fill unmet clinical requirements. Monoclonal antibody therapies are a form of treatment utilizing laboratory-engineered antibodies specifically designed to target distinct antigens present on cancer cells, thereby aiding the immune system in recognizing and combating them more effectively. As an illustration, in September 2024, Pfizer Inc., a pharmaceutical and biotechnology corporation based in the US, announced positive results from a Phase II clinical trial concerning ponsegromab, a monoclonal antibody specifically targeting Growth/Differentiation Factor 15 (GDF-15). The favorable data from this study provides optimism for a novel treatment approach for patients afflicted with this debilitating condition, given the current scarcity of effective therapies. The Phase 2 trial outcomes indicate significant progress in addressing the fundamental inflammatory processes that contribute to muscle deterioration and weight reduction in cancer patients. This therapeutic strategy seeks not only to improve physical functionality but also to uplift the overall quality of life for individuals with cancer, marking a crucial progression in oncology treatment.
Which Major Firms Are Strengthening Their Position In The Cancer Anorexia-Cachexia Syndrome (CACS) Market?
Major companies operating in the cancer anorexia-cachexia syndrome (cacs) market are Pfizer Inc., Merck & Co. Inc., Ono Pharmaceutical Co. Ltd., Mundipharma International Limited, Yuhan Corporation, Helsinn Healthcare SA, AVEO Pharmaceuticals Inc., NGM Biopharmaceuticals Inc., Larix Bioscience LLC, Aeterna Zentaris Inc., Artelo Biosciences Inc., Sapphire Therapeutics Inc., Endevica Bio, AAVogen Inc., Actimed Therapeutics Ltd., Aphios Corporation, Betula Pharmaceuticals AB, Cannabics Pharmaceuticals Inc., Creative Medical Technology Holdings Inc., Abreos Biosciences Inc.
Access The Complete Report For Deeper Market Insights:
Which Region Is Anticipated To See The Fastest Growth In The Cancer Anorexia-Cachexia Syndrome (CACS) Market?
North America was the largest region in the cancer anorexia-cachexia (CACS) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer anorexia-cachexia syndrome (cacs) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request Your Customized Cancer Anorexia-Cachexia Syndrome (CACS) Market Research Report for Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=21125&type=smp
Browse Through More Reports Similar to the Global Cancer Anorexia-Cachexia Syndrome (CACS) Market 2026, By The Business Research Company
Progressive Ataxia And Weakness Disorders Market Report 2026
Anorectal Disorders Treatment Market Report 2026
https://www.thebusinessresearchcompany.com/report/anorectal-disorders-treatment-global-market-report
Oncology Nutrition Market Report 2026
https://www.thebusinessresearchcompany.com/report/oncology-nutrition-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
